 |
|||||||||||||||
|
|
|||||||||||||||
|
 |
|||
| Spring Meeting Trial Reports: 2011 / 2010 / 2009 | |||
| ID | Study Title | Status | |
| IND.163 | A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients with Recurrent/Metastatic Breast Cancer MORE... | Permanently Closed | |
| IND.164 | A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination with Docetaxel in Advanced Breast Cancer MORE... | Permanently Closed | |
| IND.197 | A Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer MORE... | On Hold | |
| IND.198 | A Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal Growth Factor Receptor (HER2) Over-Expressing Metastatic Breast Cancer MORE... | On Hold | |
| MA.12 | Double-Blind Randomized Trial of Tamoxifen versus Placebo in Patients with Node Positive or High Risk Node Negative Breast Cancer Who Have Completed CMF, CEF or AC Adjuvant Chemotherapy | Permanently Closed | |
| MA.14 | A Randomized Trial of Antiestrogen Therapy versus Combined Antiestrogen and Octreotide Lar Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women | Permanently Closed | |
| MA.17 | A Phase III Randomized Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen MORE... | Closed | |
| MA.17B | The Influence of Letrozole on Bone Mineral Density in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen. A Companion Study to MA.17 MORE... | Permanently Closed | |
| MA.17L | The Influence of Letrozole on Serum Lipid Concentrations in Women with Primary Breast Cancer Who Have Completed Five Years of Adjuvant Tamoxifen. A Companion Study to MA.17 MORE... | Permanently Closed | |
| MA.17R | A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study) MORE... | Closed | |
| MA.20 | A Phase III Study of Regional Radiation Therapy in Early Breast Cancer MORE... | Closed | |
| MA.21 | A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed by Paclitaxel versus Sequenced AC Followed by Paclitaxel Versus CEF as Therapy for Premenopausal Women and Early Postmenopausal Women Who Have Had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer MORE... | Closed | |
| MA.22 | Phase I/II Study of Increasing Doses of Epirubicin and Docetaxel Plus Pegfilgrastim for Locally Advanced or Inflammatory Breast Cancer MORE... | Phase IIB Closed PhaseIB: Closed |
|
|
MA.23 EORTC 10951 |
Randomized Phase II-III Study in First Line Hormonal Treatment for Metastatic Breast Cancer with Exemestane or Tamoxifen in Postmenopausal Patients MORE... | Permanently Closed | |
|
MA.24 BIG B016348 |
A Randomized Three-Arm Multi-Centre Comparison of 1 Year and 2 Years of Herceptin® versus No Herceptin® in Women With HER2-positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy MORE... | Closed | |
|
MA.25 SWOG 9927 |
Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women with One to Three Positive Axillary Nodes (SWOG: S9927) MORE... | Permanently Closed | |
|
MA.26 RTOG 9804 |
Phase III Trial of Observation +/- Tamoxifen Versus RT +/- Tamoxifen for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast MORE... | Closed | |
| MA.27 | A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer MORE... | Permanently Closed | |
| MA.27B | The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Postmenopausal Women with Primary Breast Cancer. A Companion Study to MA.27 MORE... | Permanently Closed | |
|
MA.27D NCCTG N0434 |
The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence. A Companion Study to NCIC CTG MA.27 MORE... | Closed | |
| MA.29 | A Feasibility Study of Pre-Operative Sunitinib (SU11248) With Multiple Pharmacodynamic Endpoints in Patients with T1c-T3 Operable Carcinoma of the Breast MORE... | Permanently Closed | |
| MA.31 | A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer MORE... | Closed | |
| MA.32 | A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer MORE... | Open | |
| MA.32F | Biobehavioural Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer (NCIC CTG MA.32 Ancillary Study led by the National Surgical Adjuvant Breast and Bowel Project) MORE... | Open | |
|
MA.33 TROG 0701 |
A Randomised Phase III Study of Radiation Doses and Fractionation Schedules for Ductal Carcinoma in Situ (DCIS) of the Breast MORE... | On Hold | |
|
MA.34 BIG 4-11 |
Chemotherapy plus Trastuzumab Given for a Total of One Year vs Chemotherapy Plus Trastuzumab and Pertuzumab Given for a Total of One Year as Adjuvant Therapy in Patients with Operable HER-2 Positive Primary Breast Cancer. APHINITY Trial MORE... | Planned | |
|
MAC.1 CALGB 49907 |
A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years or Older with Node Positive or Node-Negative Breast Cancer MORE... | Closed | |
|
MAC.2 NSABP B-33 |
A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3 N0-1 Mo Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy (NSABP: B-33) MORE... | Closed | |
|
MAC.3 ECOG E2100 |
A Randomized Phase III Trial of Paclitaxel versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer MORE... | Permanently Closed | |
|
MAC.4 IBCSG 24-02 |
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer MORE... | Closed | |
|
MAC.5 IBCSG 25-02 |
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer MORE... | Closed | |
|
MAC.6 IBCSG 26-02 |
A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy MORE... | Closed | |
|
MAC.7 SWOG S0226 |
Phase III Randomized Trial of Anastrozole versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer MORE... | Closed | |
|
MAC.8 NSABP B-37 |
A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer MORE... | Closed | |
|
MAC.9 SWOG S0307 |
Randomized Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer MORE... | Closed | |
|
MAC.11 SWOG S0221 |
A Phase III Trial of Continuous Schedule AC + G vs Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer MORE... | Closed | |
|
MAC.12 ECOG PACCT-1 |
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial MORE... | Closed | |
|
MAC.13 NCCTG N063D |
ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their Sequence and their Combination in Patients with HER2/Erbb2 Positive Primary Breast Cancer MORE... |
Closed | |
|
MAC.14 ECOG 2108 |
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumour in Patients with Metastatic Breast Cancer MORE... | Open | |
|
MAC.15 SWOG S1007 |
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less MORE... | Open | |
| MAP.1 | A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer As Evidenced By High Breast Density MORE... | Permanently Closed | |
| MAP.2 | A Randomized Study of the Effect of Exemestane (Aromasin) versus Placebo on Breast Density in Postmenopausal Women at Increased Risk for Development of Breast Cancer MORE... | Permanently Closed | |
| MAP.3 | A Phase III Randomized Study of Exemestane versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer MORE... | Closed | |
| MAP.3B | The Influence of Five Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer. A Companion Study to MAP.3 MORE... | Closed | |
| If you have any questions, comments or suggestions, please contact our |